多西他赛同步放化疗治疗T2期喉癌
Concurrent chemoradiotherapy with docetaxel for T2 laryngeal carcinoma.
作者信息
Okami Kenji, Hamano Takahide, Takeo Teruhisa, Sakai Akihiro, Onuki Junichi, Odagiri Kyoko, Tamai Yoshifumi, Ohizumi Yukio, Iida Masahiro
机构信息
Department of Otolaryngology, School of Medicine, Tokai University, Isehara, Japan.
出版信息
Tokai J Exp Clin Med. 2008 Sep 20;33(3):130-4.
OBJECTIVE
To evaluate the efficacy and safety of concurrent chemoradiotherapy with docetaxel (DOC) for T2 laryngeal carcinoma.
METHOD
Twelve patients with T2 laryngeal cancer received concurrent chemoradiotherapy (60-70Gy) with weekly DOC (10 mg/m2) (CCRT group). The clinical files of the patients were retrospectively reviewed and survival rates and laryngeal preservation rates were analyzed compared with the group treated with conventional radiation therapy alone (RT group).
RESULTS
Complete response was observed in 11 of 12 patients (91.7%) in the CCRT group. Overall 5-year survival rates by Kaplan-Meier's method were 90% for the CCRT group and 78% for the RT group. The disease free survival with anterior commisure involvement was 90% in CCRT group and 53% in RT group, respectively. Toxicity over grade III was noticed in 3 patients.
CONCLUSION
Concurrent chemoradiotherapy with DOC is a feasible and effective treatment modality for organ preservation in T2 laryngeal cancer in the outpatient setting. Efficacy and safety of this treatment modality in an outpatient setting were discussed.
目的
评估多西他赛（DOC）同步放化疗治疗T2期喉癌的疗效和安全性。
方法
12例T2期喉癌患者接受同步放化疗（60 - 70Gy），每周使用多西他赛（10mg/m²）（CCRT组）。回顾性分析患者的临床资料，与单纯接受传统放疗的组（RT组）比较生存率和喉保留率。
结果
CCRT组12例患者中有11例（91.7%）观察到完全缓解。采用Kaplan-Meier法计算的5年总生存率，CCRT组为90%，RT组为78%。前联合受累患者的无病生存率，CCRT组为90%，RT组为53%。3例患者出现Ⅲ级以上毒性反应。
结论
门诊环境下，多西他赛同步放化疗是T2期喉癌器官保留的一种可行且有效的治疗方式。讨论了这种治疗方式在门诊环境下的疗效和安全性。
Zotero 插件